Lymphoma Clinical Trials

Showing 281-300 of 2,926 trials

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

NCT04161248

The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects. The study treatment is new agents in combination with R-GDP or an equivalent regimen.

Lymphoma, B-Cell

Canadian Cancer Trials Group18 participantsStarted Sep 2020

Vancouver, British Columbia, Canada • Kingston, Ontario, Canada • Toronto, Ontario, Canada +1 more locations

RECRUITINGPhase 2

Venetoclax and Decitabine in R/R T-ALL

NCT06712121

The goal of this phase 2 clinical trial is to test the efficacy of decitabine and venetoclax combination chemotherapy in relapsed or refractory adult T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. This study use a modified regimen of decitabine and venetoclax.

T Lymphoblastic Leukemia/Lymphoma

Seoul National University Hospital28 participantsStarted Jan 2025

Seongnam-si, South Korea • Seoul, South Korea • Seoul, South Korea

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Venetoclax and Decitabine in R/R T-ALL

Related Searches

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Expanded Access to Venetoclax

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)

A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Venetoclax Plus Inotuzumab for B-ALL

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma